9. Definitions and results of humoral response evaluation in other antigen‐specific immunotherapy studies.
| Study | N | Target antigen(s) | Analysed | Assay | Positive if: | % positive |
| Antonilli 2016 | 10 | MUC1 ± ErbB1 ± CEA | no | |||
| Berinstein 2012 | 6 | topoisomerase IIα, integrin β8 subunit precursor, ABI‐binding protein C3, TACE/ADAM17, junction plakglobin, EDDR1, BAP31 | no | |||
| Berinstein 2013 | 19 | survivin | no | |||
| Brossart 2000 | 3 | Her‐2/Neu, MUC1 | no | |||
| Chianese‐Bullock 2008 | 9 | FBP, Her‐2/Neu, MAGE‐A1 | no | |||
| Chu 2012 | 11 | Her‐2/Neu, hTERT, PADRE | no | |||
| Diefenbach 2008 | 6 | NY‐ESO‐1 | yes | unknown | unknown | not reported |
| Dijkgraaf 2015 | 6 | p53 | no | |||
| Dhodapkar 2012 | 9 | NY‐ESO‐1 | yes | ELISA | > 100 | 0% |
| Freedman 1998 | 21 | CEA | yes | ELISA | ≥ 2× pretreatment and > mean + 2 SD of 10 normal sera | 0% |
| Galanis 2010 | 63 | MUC1 | yes | unknown | unknown | 0% |
| Goh 2013 | 6 | CYP1B1 | no | |||
| Gray 2016 | 56 | MUC1 | yes | ELISA | unknown | No response measured |
| Gribben 2005 | 3 | CEA, MUC1 | no | |||
| Gulley 2008 | 30 | Sialyl‐Tn | no | |||
| Imhof 2013 | 15 | TERT, survivin | no | |||
| Kaumaya 2009 | 5 | Her‐2/Neu | yes | ELISA | high response: > 0.6 intermediate response: 0.2 to 0.6 |
60% high responses, 40% intermediate responses |
| Kawano 2014 | 42 | personalised (max 4 out of 31 vacinne candidates) | yes | Luminex assay | 1 out of 4 vaccine‐specific IgG titers is 2‐fold higher than pre‐vaccination | 6 vaccinations: 16/42 12 vaccinations: 29/30 |
| Kobayashi 2014 | 56 | WT1 ± MUC1 ± CA‐125 | no | |||
| Le 2012 | 2 | mesothelin | no | |||
| Leffers 2009a | 20 | p53 | yes | unknown | unknown | pre‐imm: 40%, post‐imm: 45% |
| Lennerz 2014 | 7 | survivin | no | |||
| Letsch 2011 | 8 | WT1 | no | |||
| MacLean 1996 | 10 | Thomsen Friedenreich | yes | ELISA | unknown | 80% IgA, 90% IgM, 90% IgG, 0% IgE |
| MacLean 1992 | 34 | Sialyl‐Tn | yes | ELISA | unknown | 96% |
| Mohebtash 2011 | 14 | MUC1, CEA | no | |||
| Morse 2011 | 8 | APC, HHR6A, BAP31, replication protein A, Abl‐binding protein 3c, cyclin I, toposiomerase IIα/β, integrin β 8 subunit precursor, CDC2, TACE, g‐catenin, EEDDR1 | no | |||
| Nishikawa 2006 | 4 | NY‐ESO‐1 | no | |||
| O'Cearbhaill 2016 | 24 | GM2, Globo‐H, Tn, TF, sTN | yes | ELISA | IgM titer > 1:80 or at least 4‐fold increase from baseline | IgM: GM2 25%, Globo‐H 8%, Tn 58%, TF 67%, sTn 92% IgG: GM2 17%, Globo‐H 58%, Tn 83%, TF 25%, sTN 67% 20/24 responded to at least 3 antigens |
| Odunsi 2007 | 18 | NY‐ESO‐1 | yes | ELISA | unknown | 22% |
| Odunsi 2012 | 22 | NY‐ESO‐1 | yes | ELISA | unknown | 50% |
| Odunsi 2014 | 12 | NY‐ESO‐1 | yes | ELISA | reciprocal titer > 100 | 4 patients remained seropositive 5/6 became seropositive no differences between cohorts. |
| Ohno 2009 | 6 | WT1 | no | |||
| Peethambaram 2009 | 4 | Her‐2/Neu | yes | ELISA | unknown | unknown |
| Rahma 2012 | 21 | p53 | no | |||
| Sabbatini 2000 | 25 | Lewis Y | yes | ELISA | unknown | 67% |
| Sabbatini 2007 | 11 | GM2, Globo‐H, Lewis Y, Tn‐MUC1, Tn(c), sTN(c), TF(c) | yes | ELISA | negative to ≥ 1:40 or 8‐fold increase | 89% ≥ 3 antigens; 22% GM2, 33% Globo‐H, 11% Lewis Y, 100% Tn‐MUC1, 44% Tn(c), 44% sTN(c), 78% TF(c) |
| Sabbatini 2012 | 28 | NY‐ESO‐1 | yes | ELISA | ≥ 100 | cohort 1: 25%, C2: 46%, C3: 91% |
| Sabbatini 2017 | 86 | Globo‐H, GM2, MUC1‐TN, TF | yes | unknown | 1:40 or 2‐fold increase | IgG: GLOBO‐H 7%, GM2 8%, MUC1‐TN 32%, MUC1 45%, TF 13% IgM: GLOBO‐H 21%, GM2 26%, MUC1‐TN 40%, MUC1 49%, TF 22% |
| Sandmaier 1999 | 7 | Sialyl‐Tn | yes | ELISA | ≥ 1:20 | 100% IgM, 80% IgG |
| Suzuki 2016 | 32 | GPC3 | no | |||
| Takeoka 2017 | 2 | NY‐ESO‐1 | yes | ELISA | optical density cutoff value 0.47 | > 2 |
| Takeuchi 2013 | 38 | HLA‐A24: FOXM1, MELK, HJURP, VEGFR1, VEGFR2 HLA‐A02: HIG2, VEGFR1, VEGFR2 |
no | |||
| Tsuda 2004 | 5 | patient‐tailored cocktail | yes | ELISA | unknown | 67% |
| Vermeij 2012 | 12 | p53 | no |
SD: standard deviation.